首頁 > 市場調查報告書 > 製藥

非專利藥糖尿病生物製劑生技仿製藥

市場調查報告書

商品編碼

1391920

基礎胰島素市場：依類型、輸送裝置、適應症、年齡層、配銷通路、地區

Basal Insulin Market, By Type, By Delivery Device, By Indication, By Age Group, By Distribution Channel, By Geography

出版日期: 2023年11月10日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

基礎胰島素市場規模預計將從 2023 年的 163 億美元增加到 2030 年的 313 億美元，預測期內複合年成長率為 9.8%。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	163億美元
實績資料	2018-2021	預測期	2023-2030
預測期複合年成長率	9.80%	2030年市場規模預測	313億美元

圖 1. 2023 年基礎胰島素全球市場佔有率(%)（依地區）

基礎胰島素是一種長效胰島素，可在白天和夜間穩定釋放胰島素，以控制糖尿病患者的血糖值。它通常用於需要胰島素治療的 1 型或 2 型糖尿病患者。基礎胰島素可維持用餐之間和用餐期間穩定的血糖值，為最佳糖尿病管理奠定基礎。

由於全球糖尿病盛行率不斷上升，全球基礎胰島素市場正經歷顯著成長。根據國際糖尿病聯盟的數據，到 2045 年，成人糖尿病患者人數預計將達到 7 億人。糖尿病患者數量的增加刺激了對基礎胰島素的需求，而基礎胰島素是糖尿病管理的重要組成部分。

市場動態：

基礎胰島素市場由多種因素驅動。糖尿病（尤其是第 2 型糖尿病）盛行率的上升是市場的主要促進因素。久坐的生活方式、不良的飲食習慣和肥胖等不健康的生活習慣導致全球糖尿病發生率不斷上升。因此，對基礎胰島素的需求預計將顯著增加。

此外，胰島素治療技術的進步也推動了市場的成長。具有改善的藥物動力學特性的胰島素類似物的開發顯著提高了基礎胰島素治療的功效和便利性。這些進步改善了血糖控制並降低了低血糖的風險。

例如，2023年10月23日，臨床階段的生物製藥公司Adsia，其合作夥伴是總公司中國的製藥公司通化東寶藥業股份有限公司，宣布推出含有Insulin Lispro和Insulin Glargine的Chaperone組合。我們宣布了三個項目的積極結果對 THDB0207 製劑進行的臨床試驗。這三項研究顯示 BC Combo 是一種有用的胰島素，結合了長效和速效胰島素的特性。從而確保餐後和空腹血糖控制。

然而，也存在阻礙基礎胰島素市場成長的因素。一些障礙包括胰島素治療的高昂費用以及某些地區獲得醫療保健的機會有限。此外，胰島素生產和分銷的嚴格監管要求給市場參與者帶來了課題。

儘管有這些課題，基礎胰島素市場仍存在一些成長機會。老年人口的增加和人們對糖尿病管理重要性的認知不斷提高預計將推動市場成長。此外，智慧胰島素輸送系統的市場開拓以及數位技術在糖尿病管理中的整合為市場參與者提供了開拓的新途徑。

本研究的主要特點

本報告對全球基礎胰島素市場進行了詳細分析，包括以2022年為基準年的預測期（2023-2030）的市場規模和年複合成長率（CAGR%）。
它揭示了各個區隔市場的潛在收益成長機會，並為該市場說明了一系列有吸引力的投資提案。
它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
根據公司亮點、產品系列、主要亮點、財務實績和策略對全球基礎胰島素市場的主要參與者進行了介紹。
該報告的見解使行銷人員和負責人能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的資訊。
全球基礎胰島素市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
相關人員可以透過用於分析全球基礎胰島素市場的各種策略矩陣來促進他們的決策。

Report Coverage	Report Details
Base Year:	2022	Market Size in 2023:	US$ 16.3 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	9.80%	2030 Value Projection:	US$ 31.3 Bn

Basal insulin is a type of long-acting insulin that provides a steady release of insulin throughout the day and night to control blood sugar levels in individuals with diabetes. It is typically prescribed for individuals with type 1 diabetes or type 2 diabetes who require insulin therapy. Basal insulin helps maintain stable blood sugar levels between meals and during periods of fasting, providing a foundation for optimal diabetes management.

The global basal insulin market is experiencing significant growth, driven by the increasing prevalence of diabetes worldwide. According to the International Diabetes Federation, the number of adults with diabetes is expected to reach 700 million by 2045. This rise in diabetes cases is fueling the demand for basal insulin, as it is an essential component of diabetes management.

Market Dynamics:

The basal insulin market is driven by several factors. The rising prevalence of diabetes, particularly type 2 diabetes, is a key driver for the market. Unhealthy lifestyle habits, such as sedentary behavior, poor diet, and obesity, are contributing to the increasing incidence of diabetes globally. As a result, the demand for basal insulin is expected to rise significantly.

In addition, advancements in insulin therapy technologies are also driving the market growth. The development of insulin analogs, which have improved pharmacokinetic properties, has significantly enhanced the efficacy and convenience of basal insulin therapy. These advancements have led to better glycemic control and reduced risks of hypoglycemia.

For instance, on October 23, 2023, Adocia, a biopharmaceutical company in the clinical stage, announced that Tonghua Dongbao Pharmaceutical Co. Ltd., a pharmaceutical company based in China, is its partner and has released positive results from three clinical studies conducted on the BioChaperone Combo THDB0207 formulation, which contains insulin lispro and insulin glargine. These three studies showed that BC Combo is a useful insulin that combines the qualities of both long-acting and rapid-acting insulin. As a result, it can guarantee glycemic control during the postprandial and fasting periods.

However, there are certain restraints that may hinder the growth of the basal insulin market. The high cost of insulin therapy and limited access to healthcare in certain regions are some of the barriers. Additionally, the stringent regulatory requirements for insulin production and distribution pose challenges for market players.

Despite these challenges, there are several opportunities for growth in the basal insulin market. The increasing geriatric population, as well as the growing awareness about the importance of diabetes management, are expected to drive the market growth. Furthermore, the development of smart insulin delivery systems and the integration of digital technologies in diabetes management present new avenues for market players to explore.

Key Features of the Study:

This report provides an in-depth analysis of the global basal insulin market including market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), with 2022 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
Key players in the global basal insulin market are profiled based on company highlights, product portfolio, key highlights, financial performance, and strategies
Key companies covered in this study include Novo Nordisk, Sanofi, Eli Lilly and Company, Biocon, Gan & Lee Pharmaceuticals, Tonghua Dongbao Pharmaceutical, United Laboratories, Merck, Wockhardt, Julphar Diabetes, Medtronic, Beta Bionics, Zealand Pharma, MannKind, Peptron, Dexcom, Senseonics, Medtrum Technologies, SOOIL Development, and Semma Therapeutics
Insights from this report would allow marketers and management authorities to make informed decisions regarding future product launches, type upgrades, market expansion, and marketing tactics
The global basal insulin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global basal insulin market

Basal Insulin Market Segmentation:

By Type
- Glargine
- Detemir
- Degludec
By Delivery Device
- Syringes
- Pens
- Pumps
- Others (Inhalers, Patches)
By Indication
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
By Age Group
- Pediatric
- Adults
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Top Companies in the Basal Insulin Market:
- Novo Nordisk
- Sanofi
- Eli Lilly and Company
- Biocon
- Gan & Lee Pharmaceuticals
- Tonghua Dongbao Pharmaceutical
- United Laboratories
- Merck
- Wockhardt
- Julphar Diabetes
- Medtronic
- Beta Bionics
- Zealand Pharma
- MannKind
- Peptron
- Dexcom
- Senseonics
- Medtrum Technologies
- SOOIL Development
- Semma Therapeutics

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Basal Insulin Market, By Type
- Global Basal Insulin Market, By Delivery Device
- Global Basal Insulin Market, By Indication
- Global Basal Insulin Market, By Age Group
- Global Basal Insulin Market, By Distribution Channel
- Global Basal Insulin Market, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
Rising prevalence of diabetes, particularly type 2 diabetes
- Restraints
High cost of insulin therapy
- Opportunities
Increasing geriatric population
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Basal Insulin Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Basal Insulin Market, By Type, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Glargine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Detemir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Degludec
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

6. Global Basal Insulin Market, By Delivery Device, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Syringes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Pens
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Pumps
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Others (Inhalers, Patches)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

7. Global Basal Insulin Market, By Indication, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Gestational Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

8. Global Basal Insulin Market, By Age Group, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

9. Global Basal Insulin Market, By Distribution Channel, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)

10. Global Basal Insulin Market, By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
China
Japan
India
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Bn)
North Africa
Central Africa
South Africa

11. Competitive Landscape

Novo Nordisk
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
Eli Lilly and Company
Biocon
Gan & Lee Pharmaceuticals
Tonghua Dongbao Pharmaceutical
United Laboratories
Merck
Wockhardt
Julphar Diabetes
Medtronic
Beta Bionics
Zealand Pharma
MannKind
Peptron
Dexcom
Senseonics
Medtrum Technologies
SOOIL Development
Semma Therapeutics
Analyst Views